Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA7 | P43166 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202354 | 0.84 | GAA (0.42) | MEN1KMT2AGAAMAPT | |
| SCHEMBL3658454 | 0.82 | FOLH1 (0.54) | FOLH1MEN1KMT2AGAAMAPT | |
| SCHEMBL1201984 | 0.79 | CA12 (0.51) | FOLH1CA12CA1CA2CA7 | |
| SCHEMBL13968018 | 0.79 | PPID (0.39) | ESR1MEN1KMT2AMAPT | |
| SCHEMBL1202417 | 0.79 | PTGS1 (0.41) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL3659623 | 0.78 | FOLH1 (0.40) | FOLH1CA12CA1CA2CA9 | |
| SCHEMBL3657305 | 0.78 | FOLH1 (0.40) | FOLH1CA12CA1CA2CA7 | |
| SCHEMBL1201874 | 0.78 | GAA (0.38) | MEN1KMT2AGAAMAPT | |
| SCHEMBL2648915 | 0.77 | SLC6A3 (0.50) | MAPT | |
| SCHEMBL1202726 | 0.77 | LMNA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2234954-B1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140364641-A1 | Tetrasubstituted Benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664249-B2 | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| CN-101945848-A | Tetrasubstituted benzenes | ENVIVO PHARMACEUTICALS INC | 2011-01-12 | — | — | CN | disclosed |
| EP-2234954-A1 | TETRASUBSTITUTED BENZENES | Envivo Pharmaceuticals, Inc. (US) | 2010-10-06 | — | — | EP | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090299072-A1 | Tetrasubstituted Benzenes | EN VIVO PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086277-A1 | TETRASUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | FOLH1 2745/4885CA12 4384/4885CA1 898/4885 |
| US-20140364641-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | FOLH1 2187/4885CA12 4428/4885CA1 1438/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | FOLH1 2745/4885CA12 4384/4885CA1 898/4885 |
| US-20090299072-A1 | Tetrasubstituted Benzenes | BACE1, BACE2, PSEN1 | FOLH1 2187/4885CA12 4428/4885CA1 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.